bioRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2023,
Номер
unknown
Опубликована: Янв. 31, 2023
Knowledge
of
the
fitness
effects
mutations
to
SARS-CoV-2
can
inform
assessment
new
variants,
design
therapeutics
resistant
escape,
and
understanding
functions
viral
proteins.
However,
experimentally
measuring
is
challenging:
we
lack
tractable
lab
assays
for
many
proteins,
comprehensive
deep
mutational
scanning
has
been
applied
only
two
Here
develop
an
approach
that
leverages
millions
publicly
available
sequences
estimate
mutations.
We
first
calculate
how
independent
occurrences
each
mutation
are
expected
be
observed
along
phylogeny
in
absence
selection.
then
compare
these
observations
actual
effect
mutation.
These
estimates
correlate
well
with
measurements.
For
most
genes,
synonymous
nearly
neutral,
stop-codon
deleterious,
amino-acid
have
a
range
effects.
some
accessory
proteins
under
little
no
provide
interactive
visualizations
all
(https://jbloomlab.github.io/SARS2-mut-fitness/).
The
framework
describe
applicable
any
virus
which
number
sufficiently
large
neutral
observed.
Cell,
Год журнала:
2022,
Номер
186(2), С. 279 - 286.e8
Опубликована: Дек. 14, 2022
The
BQ
and
XBB
subvariants
of
SARS-CoV-2
Omicron
are
now
rapidly
expanding,
possibly
due
to
altered
antibody
evasion
properties
deriving
from
their
additional
spike
mutations.
Here,
we
report
that
neutralization
BQ.1,
BQ.1.1,
XBB,
XBB.1
by
sera
vaccinees
infected
persons
was
markedly
impaired,
including
individuals
boosted
with
a
WA1/BA.5
bivalent
mRNA
vaccine.
Titers
against
were
lower
13-
81-fold
66-
155-fold,
respectively,
far
beyond
what
had
been
observed
date.
Monoclonal
antibodies
capable
neutralizing
the
original
variant
largely
inactive
these
new
subvariants,
responsible
individual
mutations
identified.
These
found
have
similar
ACE2-binding
affinities
as
predecessors.
Together,
our
findings
indicate
present
serious
threats
current
COVID-19
vaccines,
render
all
authorized
antibodies,
may
gained
dominance
in
population
because
advantage
evading
antibodies.
Abstract
Continuous
evolution
of
Omicron
has
led
to
a
rapid
and
simultaneous
emergence
numerous
variants
that
display
growth
advantages
over
BA.5
(ref.
1
).
Despite
their
divergent
evolutionary
courses,
mutations
on
receptor-binding
domain
(RBD)
converge
several
hotspots.
The
driving
force
destination
such
sudden
convergent
its
effect
humoral
immunity
remain
unclear.
Here
we
demonstrate
these
can
cause
evasion
neutralizing
antibody
drugs
convalescent
plasma,
including
those
from
breakthrough
infection,
while
maintaining
sufficient
ACE2-binding
capability.
BQ.1.1.10
(BQ.1.1
+
Y144del),
BA.4.6.3,
XBB
CH.1.1
are
the
most
antibody-evasive
strains
tested.
To
delineate
origin
evolution,
determined
escape
mutation
profiles
neutralization
activity
monoclonal
antibodies
isolated
individuals
who
had
BA.2
infections
2,3
.
Owing
immune
imprinting,
especially
infection
reduced
diversity
binding
sites
increased
proportions
non-neutralizing
clones,
which,
in
turn,
focused
pressure
promoted
RBD.
Moreover,
show
RBD
could
be
accurately
inferred
by
deep
mutational
scanning
4,5
,
trends
BA.2.75
subvariants
well
foreseen
through
constructed
pseudovirus
mutants.
These
results
suggest
current
herd
vaccine
boosters
may
not
efficiently
prevent
variants.
Cell Host & Microbe,
Год журнала:
2022,
Номер
30(11), С. 1527 - 1539.e5
Опубликована: Окт. 4, 2022
Recently
emerged
SARS-CoV-2
Omicron
subvariant,
BA.2.75,
displayed
a
growth
advantage
over
circulating
BA.2.38,
BA.2.76,
and
BA.5
in
India.
However,
the
underlying
mechanisms
for
enhanced
infectivity,
especially
compared
with
BA.5,
remain
unclear.
Here,
we
show
that
BA.2.75
exhibits
substantially
higher
affinity
host
receptor
angiotensin-converting
enzyme
2
(ACE2)
than
other
variants.
Structural
analyses
of
spike
shows
its
decreased
thermostability
increased
frequency
binding
domain
(RBD)
"up"
conformation
under
acidic
conditions,
suggesting
low-pH-endosomal
cell
entry.
Relative
to
BA.4/BA.5,
reduced
evasion
humoral
immunity
from
BA.1/BA.2
breakthrough-infection
convalescent
plasma
but
greater
Delta
plasma.
also
weaker
neutralization
against
mainly
due
BA.2.75's
distinct
neutralizing
antibody
(NAb)
escape
pattern.
Antibody
therapeutics
Evusheld
Bebtelovimab
effective
BA.2.75.
These
results
suggest
may
prevail
after
receptor-binding
capability
could
support
further
immune-evasive
mutations.
Nature,
Год журнала:
2023,
Номер
625(7993), С. 148 - 156
Опубликована: Ноя. 22, 2023
Abstract
The
continuing
emergence
of
SARS-CoV-2
variants
highlights
the
need
to
update
COVID-19
vaccine
compositions.
However,
immune
imprinting
induced
by
vaccination
based
on
ancestral
(hereafter
referred
as
WT)
strain
would
compromise
antibody
response
Omicron-based
boosters
1–5
.
Vaccination
strategies
counter
are
critically
needed.
Here
we
investigated
degree
and
dynamics
in
mouse
models
human
cohorts,
especially
focusing
role
repeated
Omicron
stimulation.
In
mice,
efficacy
single
boosting
is
heavily
limited
when
using
that
antigenically
distinct
from
WT—such
XBB
variant—and
this
concerning
situation
could
be
mitigated
a
second
booster.
Similarly,
humans,
infections
alleviate
WT
vaccination-induced
generate
broad
neutralization
responses
both
plasma
nasal
mucosa.
Notably,
deep
mutational
scanning-based
epitope
characterization
781
receptor-binding
domain
(RBD)-targeting
monoclonal
antibodies
isolated
infection
revealed
double
exposure
induce
large
proportion
matured
Omicron-specific
have
RBD
epitopes
WT-induced
antibodies.
Consequently,
was
largely
mitigated,
bias
towards
non-neutralizing
observed
exposures
restored.
On
basis
scanning
profiles,
identified
evolution
hotspots
XBB.1.5
demonstrated
these
mutations
further
boost
immune-evasion
capability
while
maintaining
high
ACE2-binding
affinity.
Our
findings
suggest
component
should
abandoned
updating
vaccines,
individuals
without
prior
receive
two
updated
boosters.
Cell,
Год журнала:
2023,
Номер
186(6), С. 1263 - 1278.e20
Опубликована: Фев. 13, 2023
A
major
challenge
in
understanding
SARS-CoV-2
evolution
is
interpreting
the
antigenic
and
functional
effects
of
emerging
mutations
viral
spike
protein.
Here,
we
describe
a
deep
mutational
scanning
platform
based
on
non-replicative
pseudotyped
lentiviruses
that
directly
quantifies
how
large
numbers
impact
antibody
neutralization
pseudovirus
infection.
We
apply
this
to
produce
libraries
Omicron
BA.1
Delta
spikes.
These
each
contain
∼7,000
distinct
amino
acid
context
up
∼135,000
unique
mutation
combinations.
use
these
map
escape
from
neutralizing
antibodies
targeting
receptor-binding
domain,
N-terminal
S2
subunit
spike.
Overall,
work
establishes
high-throughput
safe
approach
measure
∼10
Nature,
Год журнала:
2023,
Номер
621(7979), С. 592 - 601
Опубликована: Авг. 30, 2023
Abstract
Currently
circulating
SARS-CoV-2
variants
have
acquired
convergent
mutations
at
hot
spots
in
the
receptor-binding
domain
1
(RBD)
of
spike
protein.
The
effects
these
on
viral
infection
and
transmission
efficacy
vaccines
therapies
remains
poorly
understood.
Here
we
demonstrate
that
recently
emerged
BQ.1.1
XBB.1.5
bind
host
ACE2
with
high
affinity
promote
membrane
fusion
more
efficiently
than
earlier
Omicron
variants.
Structures
BQ.1.1,
XBB.1
BN.1
RBDs
bound
to
fragment
antigen-binding
region
S309
antibody
(the
parent
for
sotrovimab)
human
explain
preservation
binding
through
conformational
selection,
altered
recognition
immune
evasion.
We
show
sotrovimab
binds
avidly
all
variants,
promotes
Fc-dependent
effector
functions
protects
mice
challenged
hamsters
XBB.1.5.
Vaccine-elicited
plasma
antibodies
cross-react
trigger
against
current
despite
a
reduced
neutralizing
activity,
suggesting
mechanism
protection
disease,
exemplified
by
S309.
Cross-reactive
RBD-directed
memory
B
cells
remained
dominant
even
after
two
exposures
spikes,
underscoring
role
persistent
imprinting.
Cell Reports,
Год журнала:
2022,
Номер
41(12), С. 111845 - 111845
Опубликована: Дек. 1, 2022
Severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
Omicron
sublineages
have
escaped
most
receptor-binding
domain
(RBD)-targeting
therapeutic
neutralizing
antibodies
(NAbs),
which
proves
that
previous
NAb
drug
screening
strategies
are
deficient
against
the
fast-evolving
SARS-CoV-2.
Better
broad
candidate
selection
methods
needed.
Here,
we
describe
a
rational
approach
for
identifying
RBD-targeting
SARS-CoV-2
cocktails.
Based
on
high-throughput
epitope
determination,
propose
drugs
should
target
non-immunodominant
RBD
epitopes
to
avoid
herd-immunity-directed
escape
mutations.
Also,
their
interacting
antigen
residues
focus
sarbecovirus
conserved
sites
and
associate
with
critical
viral
functions,
making
antibody-escaping
mutations
less
likely
appear.
Following
these
criteria,
featured
non-competing
antibody
cocktail,
SA55+SA58,
is
identified
from
large
collection
of
NAbs
isolated
SARS-CoV-2-vaccinated
SARS
convalescents.
SA55+SA58
potently
neutralizes
ACE2-utilizing
sarbecoviruses,
including
circulating
variants,
could
serve
as
prophylactics
offer
long-term
protection,
especially
individuals
who
immunocompromised
or
high-risk
comorbidities.
Knowledge
of
the
fitness
effects
mutations
to
SARS-CoV-2
can
inform
assessment
new
variants,
design
therapeutics
resistant
escape,
and
understanding
functions
viral
proteins.
However,
experimentally
measuring
is
challenging:
we
lack
tractable
lab
assays
for
many
proteins,
comprehensive
deep
mutational
scanning
has
been
applied
only
two
Here,
develop
an
approach
that
leverages
millions
publicly
available
sequences
estimate
mutations.
We
first
calculate
how
independent
occurrences
each
mutation
are
expected
be
observed
along
phylogeny
in
absence
selection.
then
compare
these
observations
actual
effect
mutation.
These
estimates
correlate
well
with
measurements.
For
most
genes,
synonymous
nearly
neutral,
stop-codon
deleterious,
amino
acid
have
a
range
effects.
some
accessory
proteins
under
little
no
provide
interactive
visualizations
all
(https://jbloomlab.github.io/SARS2-mut-fitness/).
The
framework
describe
applicable
any
virus
which
number
sufficiently
large
neutral
observed.